NAD injection side effects and safety

Key takeaways

• Most NAD injection side effects are mild and dose-dependent, resolving within minutes to hours
• Injection site reactions (redness, swelling, mild pain) are the most common complaint
• Nausea, flushing, and abdominal discomfort occur more frequently at doses above 250-300 mg
• NAD+ precursor trials (NMN, NR) report no serious adverse events across thousands of participants
• Starting with lower doses (50-100 mg) and titrating up reduces the frequency of side effects
• NAD injections cause fewer side effects than IV NAD+ drips, which often produce chest tightness and cramping

NAD injections are generally well-tolerated, but “generally well-tolerated” does not mean side-effect-free. Knowing what to expect helps you recognize normal reactions, manage discomfort, and identify the rare situation that warrants medical attention.

This guide covers the actual side effect profile based on clinical experience with injectable NAD+ and published safety data from NAD+ precursor trials.

Common side effects

These occur in a meaningful percentage of patients and are considered expected reactions rather than complications.

Injection site reactions

The most frequently reported side effect. Patients may experience redness, swelling, warmth, or mild pain at the injection site. NAD+ solutions can cause a stinging or burning sensation during injection, particularly at higher concentrations.

These reactions typically resolve within 30-60 minutes. Proper injection technique helps: rotating sites, using the correct needle gauge, and injecting slowly all reduce local irritation. Our guides on how to inject peptides and peptide injection sites cover best practices.

Nausea

Nausea is dose-dependent. It occurs infrequently at doses under 200 mg and becomes more common above 300 mg. IV NAD+ therapy is notorious for producing nausea during infusion, particularly when the drip rate is too fast. Subcutaneous injections produce less intense nausea because the absorption is gradual rather than flooding the bloodstream at once.

When nausea occurs with subcutaneous injections, it typically lasts 15-30 minutes and resolves without treatment. Eating a small meal before injection and staying hydrated can reduce this effect.

Flushing and warmth

Some patients experience facial flushing, a feeling of warmth, or mild skin reddening after injection. This is related to NAD+‘s role in cellular signaling pathways and is not dangerous. It resembles the niacin flush that occurs with high-dose vitamin B3 supplementation, though typically milder.

Flushing usually appears within 10-20 minutes of injection and subsides within an hour.

Lightheadedness

Transient lightheadedness or dizziness can occur, especially with the first few injections. This may be related to shifts in cellular energy metabolism as NAD+ levels change. Sitting or lying down during and immediately after injection minimizes any risk from lightheadedness.

Less common side effects

These occur in a smaller percentage of patients and are typically associated with higher doses or individual sensitivity.

Abdominal cramping

Some patients report mild abdominal cramping or discomfort, particularly during the first week of treatment. This is more common with IV NAD+ therapy than with subcutaneous injections. The cramping is temporary and does not indicate digestive pathology.

Headache

Occasional headaches have been reported, usually mild and short-lived. Staying well-hydrated before and after injection reduces this risk. If headaches persist across multiple sessions, discuss dose adjustment with your provider.

Muscle soreness

Localized or mild generalized muscle soreness can occur, potentially related to changes in cellular energy dynamics. This is uncommon and typically limited to the first few treatments.

Heart rate changes

Some patients notice a temporary increase in heart rate after injection. This is typically mild (5-15 bpm above resting) and resolves within an hour. Patients with pre-existing cardiac conditions should discuss NAD therapy with their cardiologist before starting.

Dose-dependent relationship

Side effect severity scales with dose. Here is the general pattern reported in clinical practice:

50-100 mg subcutaneously: Minimal side effects. Mild injection site reaction possible. This is why most protocols start here.

100-250 mg subcutaneously: Mild nausea and flushing possible in some patients. Most tolerate this range without difficulty.

250-500 mg subcutaneously: Nausea, flushing, and cramping become more likely. This range is typically reached only after the patient has demonstrated tolerance at lower doses.

500+ mg subcutaneously: Side effects are common at this level. Most providers keep subcutaneous doses below 500 mg for this reason.

By comparison, IV NAD+ infusions at 250-1,000 mg frequently cause significant nausea, chest tightness, cramping, and anxiety during the infusion. The rapid delivery directly into the bloodstream produces higher peak concentrations that the body reacts to more intensely.

For dosing details, see our NAD injection dosage guide.

Safety data from clinical trials

Most of the formal safety data for NAD+ therapy comes from oral precursor trials rather than injectable NAD+ studies. Here is what those trials found:

NMN safety in humans: A 2023 review in Advances in Nutrition analyzed safety data across multiple NMN clinical trials. No serious adverse events were reported at doses up to 1,250 mg/day [1]. A 2023 multicenter, double-blind, placebo-controlled trial of NMN at 300-900 mg/day in 80 healthy adults found no clinically significant safety concerns [2].

Long-term NMN safety: A 2024 study followed healthy Japanese men taking NMN for 12 months. The treatment was safe with no adverse effects on liver function, kidney function, or blood counts [3].

NR safety in humans: A randomized, placebo-controlled trial of nicotinamide riboside in obese men found it was safe and well-tolerated [4]. A separate trial of NR plus pterostilbene confirmed that repeat dosing safely and sustainably increased NAD+ levels [5].

NAD+ precursor safety review: A 2024 review by Guarente, Sinclair, and colleagues in Cell Metabolism summarized the safety of NAD+-boosting interventions across human trials, noting a generally favorable safety profile for both NMN and NR supplementation [6].

These trials establish that raising NAD+ levels through various routes does not produce serious toxicity. The injectable route has not been subject to the same level of formal study, but the known safety of the molecule itself, combined with extensive clinical use of IV NAD+ therapy, provides reasonable confidence.

Who should avoid NAD injections

Certain groups should use caution or avoid NAD therapy:

• Active cancer patients. NAD+ supports cellular growth and repair, which could theoretically benefit cancer cells as well as healthy cells [7]. Patients with active malignancies should discuss NAD therapy with their oncologist. This concern is theoretical rather than demonstrated in clinical settings, but caution is warranted.
• Pregnant or breastfeeding women. Insufficient safety data exists for NAD+ therapy during pregnancy or lactation.
• People on certain medications. NAD+ interacts with metabolic pathways that could affect drug metabolism. Discuss your full medication list with a provider.
• People with severe liver or kidney disease. These organs process and clear metabolites. Impaired function could alter NAD+ metabolism unpredictably.

NAD injections vs IV side effects comparison

IV NAD+ therapy is better documented in clinical settings, and the side effect comparison is relevant:

IV infusions commonly cause chest tightness or pressure, significant nausea, abdominal cramping, anxiety, and a feeling of intense warmth during the infusion. These effects are related to the rapid spike in blood NAD+ levels.

Subcutaneous injections produce a gentler absorption curve. The same molecule enters the body, but over hours rather than minutes. This reduces peak blood concentrations and correspondingly reduces the intensity of side effects.

Patients who could not tolerate IV NAD+ therapy sometimes do well with subcutaneous injections at equivalent or lower doses because of this pharmacokinetic difference.

How to minimize side effects

Practical steps to reduce the likelihood and intensity of side effects:

• Start with 50-100 mg and increase gradually over several sessions
• Eat a light meal 30-60 minutes before injecting
• Stay hydrated before and after injection
• Inject slowly rather than pushing the plunger quickly
• Rotate injection sites between abdomen, thigh, and upper arm
• Time injections for when you can sit comfortably for 30 minutes afterward
• Keep a log of doses and any reactions to help your provider optimize your protocol

If you are new to self-injection, our guide on peptide injections covers the full technique. For context on side effects across the peptide therapy space, see peptide side effects.

When to contact your provider

Most NAD injection side effects resolve on their own within an hour. Contact your provider if you experience:

• Side effects that persist beyond 24 hours
• Severe nausea or vomiting
• Chest pain (not just mild warmth or flushing)
• Significant swelling or redness at the injection site that spreads or worsens
• Signs of allergic reaction (hives, difficulty breathing, facial swelling)
• Heart palpitations lasting more than 30 minutes

Serious adverse events from NAD injections are rare in clinical practice, but knowing the signs that warrant attention is part of responsible self-administration.

Frequently asked questions

Do NAD injections hurt?▼

The injection itself is comparable to other subcutaneous injections, similar to what patients describe with peptide therapy or insulin. NAD+ solution can cause a brief burning or stinging at the injection site that fades within minutes. Using proper technique and rotating sites minimizes discomfort.

How long do NAD injection side effects last?▼

Most side effects resolve within 30-60 minutes. Injection site redness may linger for a few hours. If side effects persist beyond 24 hours, contact your prescribing provider.

Are NAD injections safer than IV drips?▼

Subcutaneous injections typically produce milder side effects than IV infusions. The slower absorption means lower peak blood concentrations, which reduces nausea, cramping, and chest tightness. Both routes deliver the same molecule and carry similar fundamental safety profiles.

Can NAD injections cause weight gain?▼

No evidence links NAD+ therapy to weight gain. NAD+ supports metabolic function and energy production. Some precursor trials showed modest improvements in metabolic markers [8]. For weight management, see our guide on peptides for weight loss.

Are there long-term risks of NAD injections?▼

Formal long-term studies of injectable NAD+ have not been published. The longest published NAD+ precursor trial followed participants for 12 months without serious adverse effects [3]. The molecule itself is naturally present in every cell, which provides some reassurance, but decades-long safety data does not yet exist.

Can I take NAD injections with other medications?▼

Discuss all medications with your provider before starting NAD therapy. NAD+ interacts with metabolic enzymes that process some drugs. Of particular note: patients on blood thinners, diabetes medications, or cancer therapies should get specific clearance.

References

1. Song Q, Zhou X, et al. The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update. Adv Nutr. 2023;14(6):1416-1435. PubMed
2. Yi L, Maier AB, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023;45(1):29-43. PubMed
3. Yamaguchi S, Irie J, et al. Safety and efficacy of long-term nicotinamide mononucleotide supplementation on metabolism, sleep, and nicotinamide adenine dinucleotide biosynthesis in healthy, middle-aged Japanese men. Endocr J. 2024;71(2):153-169. PubMed
4. Dollerup OL, Christensen B, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018;108(2):343-353. PubMed
5. Dellinger RW, Santos SR, et al. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. NPJ Aging Mech Dis. 2017;3:17. PubMed
6. Guarente L, Sinclair DA, et al. Human trials exploring anti-aging medicines. Cell Metab. 2024;36(2):354-376. PubMed
7. NAD+ metabolism, stemness, the immune response, and cancer. Signal Transduct Target Ther. 2021;6(1):2. PubMed
8. Zhang J, Poon ET, et al. Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials. Crit Rev Food Sci Nutr. 2025;65(8):1285-1296. PubMed